Thoracic Diseases, Thoracic Surgery
Conditions
Brief summary
Exploring the optimal interval time in patients with the clinical diagnosis of lung cancer or mediastinal tumors indicated for thoracic surgeries after SARS-CoV-2 infection by comparing 30-day mortality and 30-day morbidity.
Interventions
OTHERObservation
Observe the 30-day mortality and 30-day morbidity.
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. The patient has fully understood the nature of this study and voluntarily agreed to participate by signing an informed consent form. 2. Participants of any gender between the ages of 18 and 85 are eligible. 3. Preoperative imaging evaluation +/- biopsies indicates that the patient has resectable lung cancer or mediastinal tumors without distant metastasis.
Exclusion criteria
1. Patients who have previously undergone lung surgery; 2. Patients previously infected with SARS-CoV-2 more than 6 months before thoracic surgery; 3. Patients who did not receive Chest computed tomography (CT) at admission or within 7 days before surgery, or whose Chest CT at admission suggests pneumonia or current infection with SARS-CoV-2 (confirmed by routine laboratory tests as positive nucleic acid in admission or on the day of surgery); 4. The elapsed time from SARS-CoV-2 diagnosis to surgery is within 4 weeks; 5. Local unresectable lesions or distant metastases are found intraoperatively.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of perioperative mortality | 30 days after surgery | 30-day mortality after surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of perioperative complications | 30 days after surgery | 30-day morbidity after surgery |
Countries
China
Outcome results
None listed